Paratek Advances Timing of Top-Line Data for Phase 3

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Paratek Advances Timing of Top-Line Data for Phase 3 Community Acquired Bacterial Pneumonia Study to the Second Quarter of 2017

BOSTON, Dec. 13, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK ), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it projects its ongoing pivotal Phase 3 clinical study evaluating omadacycline for the treatment of community acquired bacterial pneumonia (CABP) will report top-line data during the second quarter of 2017.  The company had previously estimated that this trial would report top-line data as early as the third quarter of 2017.  The revised estimate reflects faster-than-expected patient enrollment in the study. This study, which is designed to assess the efficacy and safety of IV to once-daily oral omadacycline compared with moxifloxacin in subjects with CABP, enrolled its first patient in November 2015.

“We’ve been very pleased with the progress of this study, and this new projected timeline further reinforces our expectation that, with a successful outcome, we will be able to file a new drug application for omadacycline for both the acute skin infections and pneumonia indications in the first half of 2018,” said Evan Loh, M.D., President and Chief Medical Officer, Paratek.  “Omadacycline offers a unique option for physicians as an IV to once-daily oral, broad spectrum antibiotic with a well characterized safety and tolerability profile.  Our recently announced positive clinical bronchoalveolar lavage pharmacokinetic data, together with our pre-clinical data, and microbiological data, further supports our confidence in omadacycline as a potential treatment for community acquired bacterial pneumonia.”

This Phase 3, randomized, double-blind, multi-center study will compare the safety and efficacy of intravenous (IV) to oral (PO) omadacycline therapy to moxifloxacin IV/PO for treating adults with CABP. The study is designed to enroll approximately 750 adult subjects in approximately 125 centers worldwide. The primary efficacy endpoint for FDA evaluation as established in the protocol is defined as the number of subjects with clinical success at the early clinical response assessment visit 72-120 hours after the first dose of study drug.  Other secondary efficacy outcome measurements will include investigator assessment of clinical response, overall survival and resolution or improvement of signs and symptoms at the post treatment evaluation visit (5-10 days after the last day of therapy).  In addition, safety and tolerability as assessed by treatment-emergent adverse events, vital sign measurements, ECGs, and laboratory values will be measured.

About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative, atypical and anaerobic bacteria. In addition to the Phase 3 trial in CABP, the Phase 3 program for omadacycline includes two other studies: In June 2016 Paratek announced positive efficacy data in a Phase 3 registration study in acute bacterial skin and skin structure infections (ABSSSI) demonstrating the efficacy and safety of intravenous (IV) to once-daily oral omadacycline compared to linezolid.  Another Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016.  Top line data from this study are expected in the second quarter of 2017.  A Phase 1B study in uncomplicated urinary tract infections (UTI) was initiated in May 2016 and positive top-line PK proof-of-principle data was reported in November 2016.  In October 2016, Paratek announced a research agreement with the U.S. Department of Defense to explore the utility of omadacycline against pathogenic agents including plague and anthrax. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration.

Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.

Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting.  Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights.  Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line Phase 3 data are expected in early 2017.

For more information, visit www.paratekpharma.com .

Forward-Looking Statements This press release contains forward-looking statements including statements related to our overall strategy, product candidates, clinical trials, prospects and expected results, including statements about the timing of advancing omadacycline and otherwise preparing for clinical trials, the potential for omadacycline to serve as an empiric monotherapy treatment option for patients suffering from ABSSSI, CABP, UTI, and other bacterial infections when resistance is of concern, the prospect of omadacycline providing broad-spectrum activity, and our having the resources to execute on our clinical trials. All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to (i) our need for substantial additional funding to complete the development and commercialization of our product candidates, (ii) our ability to raise the capital to do so, (iii) our ability to develop our drug candidates for potential commercialization, (iv) the advancement of omadacycline Phase 3 trials for ABSSSI and CABP, (v) the potential for omadacycline to be successfully developed for use as a first-line empiric monotherapy for patients suffering from serious community-acquired bacterial infections, (vi) the potential of omadacycline to become the primary antibiotic choice of physicians for the treatment of serious community-acquired bacterial infections, (vii) the ability of our supply chain to provide adequate supply to satisfy our clinical and commercial demand (viii) the potential use and effectiveness of sarecycline for the treatment of acne and rosacea in the community setting, and (ix) the timing of the Phase 3 program in moderate-severe acne for sarecycline, risks that data to date and trends may not be predictive of future results, risks related to the conduct of our clinical trials, and risks that our clinical trials and product candidates do not receive regulatory approval.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2015, and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

CONTACTS: Media: Michael Lampe Scient Public Relations (484) 575-5040 michael@scientpr.com Investors: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading
Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 97

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 30

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 87

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 129

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Laboratory Filtration Market Expands to $6.55B by 2031

Updated Category News Views 42

A Niche Ready to Explode The laboratory filtration market isn't exactly the sort of thing that grabs headlines in the business section, but its growth is worth giving a second look. By 2031, this market's expected to hit $6.55 billion—up from $4.49 billion in 2026. If you think that's not impressive, chew on a 7.9% CAGR for the next few years. That's like watching your...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 38

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Africa Tech Festival 2026: A Digital Turning Point

Updated Category News Views 96

Setting the Stage for Digital Advancement in Africa Come mid-November, Cape Town's gonna be buzzing with the clatter of tech titans and financial honchos making their annual pilgrimage to the Africa Tech Festival. This ain't just a conference shindig—with names like Naspers, MTN, Meta, and Amazon on the docket, it's a darn convention shaping the continent's future...

Continue Reading
Ericsson Completes Major Buyback in November Burst

Updated Category News Views 81

Ericsson's Aggressive Share Repurchase Strategy Ericsson's share buyback spree might not be the first rodeo for seasoned investors out there, but their recent grab between November 9th and 13th surely made a few heads turn. The telecom giant snatched up a neat pile of 500,000 of its own Class B shares, maintaining the steady tick of their ambitious buyback program. It's...

Continue Reading

Top 5 Most Recently Viewed Articles

Octopus AIM VCT plc Announces Securities Purchase Update

Updated Category News Views 173

Overview of Recent Securities Purchase by Octopus AIM VCT plc Octopus AIM VCT plc has made a significant move in the investment landscape with its recent transaction involving the purchase of its own securities. This strategic decision, which involved the cancellation of 723,329 ordinary shares, highlights the company's commitment to managing its capital structure...

Continue Reading
Bradford T Whitmore Makes Significant Investment in Ultralife

Updated Category News Views 116

Notable Insider Investment in Ultralife It recently came to light through official filings that Bradford T Whitmore, a Board Member of Ultralife (NASDAQ: ULBI), has made a substantial insider purchase. This move of buying shares resonates with his confidence in the company's growth trajectory. Understanding the Purchase Whitmore's investment entailed the acquisition of...

Continue Reading
Innovative Partnership to Enhance Youth Care in California

Updated Category News Views 202

Transforming Youth Care Through Innovation Qualifacts, a prominent leader in AI-driven electronic health record (EHR) software, has announced an exciting partnership with Open Line Group Homes. This collaboration aims to revolutionize the billing procedures and operational workflows within residential care facilities catering to youth. With the growing need for efficient,...

Continue Reading
Achilles Therapeutics Transfers Key Assets to AstraZeneca

Updated Category News Views 184

Achilles Therapeutics Transfers Key Assets to AstraZeneca - Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - Recently, Achilles Therapeutics plc (ACHL) announced a pivotal deal, transferring the commercial license of essential data and...

Continue Reading
Insights into Opendoor Technologies (OPEN) Market Performance

Updated Category News Views 311

Recent Developments in Opendoor Technologies Stock Opendoor Technologies Inc (NASDAQ: OPEN) has been capturing investors' attention recently, showcasing a compelling rally that illustrates a resurgence of optimism. The stock, known for its dynamic trading patterns, experienced a significant upswing, climbing more than 50% within just a week. This movement brought its...

Continue Reading